Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094337 | 0.82 | KMT2A (0.54) | MEN1KMT2ARAB9APOLBHSD17B10 | |
| SCHEMBL16589375 | 0.79 | FFAR1 (0.45) | ALDH1A1 | |
| SCHEMBL2553482 | 0.78 | PPARA (0.49) | POLBALDH1A1CYP1A2LMNAMAPK1 | |
| SCHEMBL6504745 | 0.78 | PPARA (0.49) | POLBALDH1A1CYP1A2LMNAMAPK1 | |
| SCHEMBL17653645 | 0.78 | PPARA (0.49) | POLBALDH1A1CYP1A2LMNAMAPK1 | |
| SCHEMBL3236680 | 0.78 | FFAR1 (0.46) | MEN1KMT2ALMNA | |
| SCHEMBL758770 | 0.78 | CPN1 (0.53) | POLBALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4854892 | 0.77 | ALDH1A1 (0.55) | MEN1KMT2ARAB9APOLBNR4A1 | |
| SCHEMBL13260957 | 0.77 | HSD17B10 (0.58) | MEN1KMT2ARAB9APOLBNR4A1 | |
| SCHEMBL10033007 | 0.77 | PPARA (0.55) | MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| US-20220354809-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2022-11-10 | — | — | US | disclosed |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2022-02-03 | — | — | US | disclosed |
| US-11046641-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2021-06-29 | — | — | US | disclosed |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LTD (IE) | 2021-04-22 | — | — | US | disclosed |
| US-10959970-B2 | Methods of treating hair related conditions | NOGRA PHARMA LIMITED (IE) | 2021-03-30 | — | — | US | disclosed |
| US-20200383942-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| US-20200188340-A1 | Methods of Treating Hair Related Conditions | GIULIANI INTERNATIONAL, LTD. (IE) | 2020-06-18 | — | — | US | disclosed |
| US-20190269637-A1 | Alkylamido Compounds and Uses Thereof | GIULIANI INTERNATIONAL, LTD. (IE) | 2019-09-05 | — | — | US | disclosed |
| US-20150087708-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | disclosed |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | disclosed |
| US-20150051285-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051285-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2015-02-19 | — | — | US | disclosed |
| US-8796334-B2 | Methods of treating hair related conditions | NOGRA PHARMA LIMITED (IE) | 2014-08-05 | — | — | US | disclosed |
| US-8796334-B2 | Methods of treating hair related conditions | NOGRA PHARMA LIMITED (IE) | 2014-08-05 | — | — | US | disclosed |
| US-8754127-B2 | Alkylamido compounds and uses thereof | NOGRA PHARMA LIMITED (IE) | 2014-06-17 | — | — | US | disclosed |
| US-8754127-B2 | Alkylamido compounds and uses thereof | NOGRA PHARMA LIMITED (IE) | 2014-06-17 | — | — | US | disclosed |
| US-20120053245-A1 | Methods of Treating Hair Related Conditions | GIULIANI INTERNATIONAL, LTD. (IE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053244-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354809-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | MEN1 4515/4885KMT2A 4005/4885RAB9A 2065/4885 |
| US-20190269637-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | MEN1 4515/4885KMT2A 4005/4885RAB9A 2065/4885 |
| US-20200383942-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | MEN1 4515/4885KMT2A 4005/4885RAB9A 2065/4885 |
| US-20150087708-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | MEN1 4490/4885KMT2A 3951/4885RAB9A 2827/4885 |
| US-20150051285-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | MEN1 4515/4885KMT2A 4005/4885RAB9A 2065/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | MEN1 4490/4885KMT2A 3951/4885RAB9A 2827/4885 |
| US-20120053245-A1 | Methods of Treating Hair Related Conditions | PPARA, PPARG, PPARD | MEN1 4764/4885KMT2A 2859/4885RAB9A 4459/4885 |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | EBP, AADAT, ALDH7A1 | MEN1 4197/4885KMT2A 2183/4885RAB9A 4066/4885 |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | MEN1 4879/4885KMT2A 3204/4885RAB9A 3521/4885 |
| US-10959970-B2 | Methods of treating hair related conditions | PPARA, PPARG, PPARD | MEN1 4764/4885KMT2A 2859/4885RAB9A 4459/4885 |
| US-20200188340-A1 | Methods of Treating Hair Related Conditions | PPARA, PPARG, PPARD | MEN1 4764/4885KMT2A 2859/4885RAB9A 4459/4885 |
| US-20120053244-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | MEN1 4515/4885KMT2A 4005/4885RAB9A 2065/4885 |
| US-11046641-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | MEN1 4490/4885KMT2A 3951/4885RAB9A 2827/4885 |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | MEN1 4490/4885KMT2A 3951/4885RAB9A 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.